Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853.
Human immunodeficiency virus (HIV) type 1-infected persons with newly diagnosed Mycobacterium avium complex (MAC) bacteremia were enrolled in an 8-week study to determine whether treatment of MAC infection is associated with decreases in plasma tumor necrosis factor (TNF)-alpha levels. Blood specimens were obtained for quantitative MAC cultures and to determine plasma levels of HIV RNA, TNF-alpha, and other proinflammatory cytokines. MAC levels decreased by 1.75 log at week 4 (P=.008) and by 2.48 log at week 8 (P=.001). Plasma TNF-alpha decreased by 0.15 log at week 4 (P=.042) and by 0. 40 log at week 8 (P=.027). Plasma interleukin (IL)-6 decreased by 0. 56 log at week 8 (P=.039). There were nonsignificant trends (P<.10) for plasma levels of IL-1beta and HIV RNA to decrease at week 8. Nonsignificant decreases in plasma levels of TNF-alpha, IL-1beta, IL-6, and HIV RNA were also seen in those individuals who remained on stable antiretroviral therapy throughout the 8 weeks of the study.
MacArthur
R D
RD
Wayne State University, Department of Medicine, Division of Infectious Diseases, Detroit, MI 48201, USA. macarthur@intmed.wayne.edu
Lederman
M M
MM
Benson
C A
CA
Chernoff
M C
MC
MacGregor
R R
RR
Spritzler
J
J
Mahon
L F
LF
Yen-Lieberman
B
B
Purvis
S
S
D017088:AIDS-Related Opportunistic Infections / Q000097:blood* / Q000188:drug therapy*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood*; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D015270:Mycobacterium avium-intracellulare Infection / Q000097:blood* / Q000188:drug therapy*; D010865:Pilot Projects; D012367:RNA, Viral / Q000032:analysis; D017828:Rifabutin / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019562:Viral Load
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D012367:RNA, Viral; D014409:Tumor Necrosis Factor-alpha; D017828:Rifabutin; D004977:Ethambutol; D017291:Clarithromycin